Find Clinical Trial

A randomised, double-blind, placebo- and olanzapine- controlled, parallel-group study to evaluate the efficacy and safety of 3 fixed doses of S 33138 in treatment of patients with an acute episode of Schizophrenia. A phase IIb, international, multicentre, 8-week study


← Back
Study Phase

Phase 2

Therapeutic Area

Neuropsychiatric Diseases

IndicationSchizophrenia
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

S033138

Active Substance CodeS033138
Protocol CodeCL2-33138-011
EudraCT Code2006-006184-23


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility